We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?

@inproceedings{Cotta2016WeNT,
  title={We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?},
  author={Menino Osbert Cotta and Jason A. Roberts and Jeffrey Lipman},
  booktitle={Critical care},
  year={2016}
}
Zander et al. [1] have recently conducted a prospective observational study to describe the variability of piperacillin (PIP) concentrations and target attainment in a heterogeneous cohort of 60 critically ill patients. An intermittent bolus dosing regimen of piperacillintazobactam (PIP-TAZ) was used 4.5 g three times daily (TID) or twice daily (BID), depending on renal function. As PIP-TAZ is largely renally excreted, it was unsurprising that the investigators found that no patient within the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 91 times over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com